Wayne Kuznar

Authored Items
Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma
Wayne Kuznar
TOP - February 2019, Vol 12, No 1 in Immunotherapy, Renal-Cell Carcinoma
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
TON - November 2018, Vol 11, No 5 in Immunotherapy
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
TON - September 2018, Vol 11, No 4 in Lynch Syndrome
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 in Colorectal Cancer
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 in Immunotherapy
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 in Conference Correspondent, Drug Updates, ASH
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
Wayne Kuznar
TON - March 2018, Vol 11, No 1 in Conference Correspondent, Drug Updates
Selecting Optimal Therapy for Chronic Lymphocytic Leukemia Is a Work in Progress
Wayne Kuznar
TON - November 2017, Vol 10, No 6 in Leukemia
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 in Gynecologic Cancers, Online First
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancers
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 in Breast Cancer
Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases Myeloma
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 in Lung Cancer
Updated NCCN Guidelines for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies
Wayne Kuznar
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, NCCN News
Duloxetine Improves Chemotherapy-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer
Wayne Kuznar
TOP - May 2017, Vol 10, No 2 in Pancreatic Cancer
Direct Access to Colonoscopy Improves Screening Rates, Adenoma Detection
Wayne Kuznar
TON - March 2017, Vol 10, No 2 in Colorectal Cancer
Daily Moderate Exercise Can Improve Outcomes in Patients with Metastatic Colorectal Cancer
Wayne Kuznar
TON - March 2017, Vol 10, No 2 in Colorectal Cancer
Internet-Generated Survivorship Care Plans Are Convenient and Customized
Wayne Kuznar
TON - March 2017, Vol 10, No 2 in Survivorship
Duloxetine Improves Chemotherapy-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer
Wayne Kuznar
TON - March 2017, Vol 10, No 2 in Rare Cancers
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Web Exclusives in Conference Correspondent, In the News
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Wayne Kuznar
Web Exclusives in Conference Correspondent, In the News
Alectinib for First-Line Treatment in NSCLC with ALK Mutation
Wayne Kuznar
TOP - November 2016, Vol 9, No 4 in Conference Correspondent
Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline
Wayne Kuznar
TOP - August 2016, Vol 9, No 3 in Guidelines
NCCN Survivorship Guidelines Update Management of Sexual Dysfunction in Cancer Survivors
Wayne Kuznar
TOP - August 2016, Vol 9, No 3 in Guidelines
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
TOP - August 2016, Vol 9, No 3 in Genitourinary Cancers
NCCN Survivorship Guidelines Update Management of Sexual Dysfunction
Wayne Kuznar
TON July 2016 Vol 9 No 4 in Guidelines
NCCN Panel Addresses Palliative Care Needs, Emphasizes Team Approach
Wayne Kuznar
TON July 2016 Vol 9 No 4 in Palliative Care
Steroid Mouth Rinse Prevents Stomatitis with Everolimus
Wayne Kuznar
TON May 2016 Vol 9 No 3 in Breast Cancer
Scan Underutilized in BRCA Carriers Undergoing Risk-Reducing Salpingo-Oophorectomy
Wayne Kuznar
TON May 2016 Vol 9 No 3 in Conference Correspondent
Scalp Cooling System Lessens Chemotherapy-Induced Alopecia
Wayne Kuznar
TON May 2016 Vol 9 No 3 in Breast Cancer
Text Messaging Application Helpful with Adherence to Endocrine Therapy
Wayne Kuznar
TOP - May 2016, Vol 9, No 2 in Technology Update
Text Messaging Application Helpful with Adherence to Endocrine Therapy
Wayne Kuznar
TON March 2016 Vol 9 No 2 in Technology Update
Counseling, Multiplex Testing May Lower Anxiety in At-Risk Patients with Cancer
Wayne Kuznar
TON March 2016 Vol 9 No 2 in Genetic Counseling
Scalp Cooling System Lessens Chemotherapy-Induced Alopecia
Wayne Kuznar
TOP - February 2016, Vol 9, No 1 in Breast Cancer
Oncology Medical Home Shows Significant Cost-Savings, Improved Care Delivery
Wayne Kuznar
TON January 2016 Vol 9 No 1 in Navigation
Oncology Specialty Pharmacy Promotes the Coordination of Care
Wayne Kuznar
TOP November 2015 Vol 8 No 4 in Practical Issues for Pharmacists
Molecular Pathways in Cancer Are Increasingly Being Exploited
Wayne Kuznar
TON November 2015 Vol 8 No 6 in Personalized Medicine
Predictive Potential of Molecular Biomarkers Promises to Enhance Precision Medicine in Oncology
Wayne Kuznar
TON November 2015 Vol 8 No 6 in Personalized Medicine
Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma
Wayne Kuznar
TOP - August 2015, Vol 8, No 3
NCCN Issues New Smoking-Cessation Guidelines for Patients with Cancer
Wayne Kuznar
TOP - August 2015, Vol 8, No 3 in Prevention
Treatment for CLL Will Incorporate More Targeted Therapies in the Near Future
Wayne Kuznar
TOP - August 2015, Vol 8, No 3 in Hematologic Cancers
New NCCN Guideline Addresses Smoking Cessation in Patients With Cancer
Wayne Kuznar
TON May 2015 Vol 8 No 3
Vosaroxin, a Quinolone Derivative, Extends Survival in Older Patients with Acute Myeloid Leukemia
Wayne Kuznar
TOP - May 2015, Vol 8, No 2 in Hematologic Cancers
Monitoring Response to TKI Therapy by PCR Improves Outcomes in Chronic Myeloid Leukemia
Wayne Kuznar
TOP - May 2015, Vol 8, No 2 in Hematologic Cancers
Immunotherapy the Newest Breakthrough in Hodgkin Lymphoma
Wayne Kuznar
TOP - February 2015, Vol 8, No 1 in Immunotherapy
Cancer Drug Pricing in the United States: What Is Driving the High Costs?
Wayne Kuznar
TOP - February 2015, Vol 8, No 1 in Conference Correspondent
Routine Imaging Costly in B-Cell Lymphoma, Rarely Picks Up Relapse After Remission
Wayne Kuznar
TON - January 2015 Vol 8 No 1 in Hematologic Cancers
Health Literacy
Wayne Kuznar
TOP - August 2014, Vol 7, No 3 in Noteworthy Numbers
Worksite Pharmacy Can Enhance Overall Drug Management of Patients With Cancer
Wayne Kuznar
TOP - August 2014, Vol 7, No 3 in Conference Correspondent
Exercise for Cancer Survivors
Wayne Kuznar
TON - July/August 2014 Vol 7 No 4 in Conference Correspondent
Prospects for Personalization of Medicine Lie in Evidence Thresholds
Wayne Kuznar
TON - July/August 2014 Vol 7 No 4 in Conference Correspondent
Skin Toxicity With Targeted Agents
Wayne Kuznar
TON - May/June 2014 Vol 7 No 3 in Supportive Care
Skin Toxicity With Targeted Agents: Treatment With Antibiotics, Topical Steroids Often Sufficient
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 in Supportive Care
Molecular Monitoring Can Provide Treatment Guidance in CML
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 in Hematologic Cancers
Hormone Therapy Poses Health Risks in Patients With Prostate Cancer
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 in Hematologic Cancers
Molecular Therapy Beyond Sorafenib in HCC: New Pathways, Targets Being Explored
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 in Genitourinary Cancers
Promising Vaccine Combination Identified for Patients With Metastatic Pancreatic Cancer
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 in Rare Cancers
Immunotherapy Holds Promise to Extend Survival in GI Cancers
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 in Personalized Medicine
Investigational Angiogenesis Inhibitor Ramucirumab Improves Survival as Second-Line Treatment
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 in Gastrointestinal Cancers
Molecular Therapy Beyond Sorafenib in HCC: New Pathways, Targets Being Explored
Wayne Kuznar
TON - March/April 2014 Vol 7 No 2 in Genitourinary Cancers
Prostate Cancer
Wayne Kuznar
TON - September 2013 Vol 6 No 8 in Noteworthy Numbers, Hematologic Cancers
Novel Agents Emerge in Initial Therapy, Refractory Setting
Wayne Kuznar
TON - September 2013 Vol 6 No 8 in Hematologic Cancers
Technology Brings No Upward Shift in Treatment of Local Prostate Cancer
Wayne Kuznar
TON - September 2013 Vol 6 No 8 in Genitourinary Cancers
Monitor Adverse Events Early With Regorafenib, Especially After Initiation
Wayne Kuznar
TOP - May 2013, Vol 6, No 2 in Supportive Care
Regorafenib Benefit in Colorectal Cancer Not Dependent on Mutations
Wayne Kuznar
TON - March 2013, Vol 6, No 2 in Colorectal Cancer
Quality of Life Drives Patient Preference for Metastatic Renal Cell Carcinoma Drug
Wayne Kuznar
TOP - August 2012, Vol 5, No 5
Most End-of-Life Costs for Patients with Cancer Are Not Drug Related
Wayne Kuznar
TOP - September 2011 Vol 4, No 6 in Conference Correspondent
Get Ready for the New Era of “Genomic Chaos” in Cancer Care
Wayne Kuznar
TOP - September 2011 Vol 4, No 6 in Conference Correspondent
Decitabine Improves Overall Survival in Older AML Patients
Wayne Kuznar
TOP - August 2011 Vol 4, No 5 in Conference Correspondent, Conference Correspondent, Hematologic Cancers
Timing of Empiric Antibiotic Administration Affects Outcomes in Febrile Neutropenia
Wayne Kuznar
TOP - February 2011, Vol 4, No 1
Last modified: June 10, 2010